🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Egypt / NCT07301918
Recruiting Not applicable

Leaf Expander Versus Hyrax Expander in Mixed Dentition Patients With Posterior Crossbite.

NCT07301918 · tracked via the Priya Life Science Egypt tracker
Phase
Not applicable
Started
2025-10-01
Last updated
2026-06-04

Condition(s) studied

Posterior CrossbiteMaxilla; Hypoplasia

Investigational drug(s) / intervention(s)

The Leaf expanderHyrax expander

The Leaf expander: The Leaf expander incorporates Nickel Titanium springs that will not require the patients' home activation

Hyrax expander: Hyrax expander incorporates a screw that requires the patients' home activation

Study summary

Design: Two-arm parallel randomized clinical trial in mixed dentition (6-12 years).

Arms: (1) 9 mm, 900 g leaf expander; (2) 9 mm Hyrax expander. Follow-up: From appliance insertion → completion of intended expansion → 6-month retention.

Primary outcome: Pain perception during the first 7 days post-insertion (daily patient-reported scale).

Secondary outcomes: Skeletal and dental changes on CBCT.

Eligibility

Sex
ALL
Min age
6 Years
Max age
12 Years
Healthy volunteers
No
Inclusion Criteria: * Male and female patients * Mixed dentition stage * Unilateral or bilateral posterior crossbite. * Patients in prepubertal stage with cervical vertebral maturation stage 1-3. * Fully erupted maxillary and mandibular permanent first molars. * Skeletal class I or II. Exclusion Criteria: * Previous orthodontic treatment. * Missing teeth. * Inadequate oral hygiene. * Patients with bad oral habits. * Patients with medical conditions. * Patients with cleft lip and palate.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Cairo University Cairo Egypt Recruiting

More Cairo University trials in Egypt

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07301918 on ClinicalTrials.gov ↗ ← All trials in Egypt